VCVaishnavi Chintala

Vaishnavi Chintala

*This is an algorithmically generated author record based on publicly available information.

Vaishnavi Chintala has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Stability‐Indicating RP‐HPLC Method Development and Validation for Determination of Impurities in Loperamide Hydrochloride Capsules Dosage Form

    by Sreenivas Pippalla, Vaishnavi Chintala

    A quality by design (QbD)‐based high‐resolution, stability‐indicating high‐performance liquid chromatography (HPLC) method was developed for determining impurities in loperamide hydrochloride (LPH) tablet dosage forms. Using this method, eight known impurities were qualified, and three degradants were quantified with excellent peak resolution. Mobile Phase‐A consisted of 0.05‐M tetrabutylammonium hydrogen phosphate buffer and acetonitrile (80:20, v/v), while Mobile Phase‐B contained the same buffer and acetonitrile (20:80, v/v). The gradient program was as follows: 0 min, MP‐A 95%, MP‐B 5%; 15 min, MP‐A 30%, MP‐B 70%; 17 min, MP‐A 30%, MP‐B 70%; 19 min, MP‐A 95%, MP‐B 5%; and 24 min, MP‐A 95%, MP‐B 5%. Chromatographic separation was performed using a column zodiac C18 (100 mm × 4.6 mm, 3.0 μm) with a flow rate of 1.5 mL/min, detection at 220 nm, an injection volume of 10 μL, and a column temperature of 35°C.Stress studies revealed LPH's sensitivity to acidic, oxidative, and thermal conditions. Under all forced degradation conditions, the purity angle was found to be less than the purity threshold, demonstrating the robustness of the method. Validation confirmed its suitability for quality analysis and stability studies in routine manufacturing processes.


  • A quality‐by‐design evaluated liquid chromatography method development and validation for the separation and quantification of nitroxoline and its impurities

    by Santhi Priya Lankalapalli, K. Vijaya Rachel, Vaishnavi Chintala, Leela Prasad Kowtharapu, Naresh Kumar Katari

    A novel, isocratic, sensitive, stability‐indicating high‐performance liquid chromatography method was developed for the separation and quantification of related substances in nitroxoline (NTL). The chromatographic separation has been achieved on Inertsil ODS‐3 V, (250 × 4.6 mm, 5 μm) at 240 nm using ethylenediamine tetraacetic acid buffer and methanol in the ratio of 60:40 v/v as mobile phase. The performance of the method has been checked as per the International Conference on Harmonization guidelines for specificity, linearity, accuracy, precision, and robustness. Regression analysis showed a correlation coefficient value greater than 0.99 for NTL and its three impurities. The detection limit of impurities was in the range of 0.01% (0.05 μg/mL)–0.22% (1.1 μg/mL) indicating the sensitivity of the newly developed method. The accuracy of the method was established based on the recovery obtained between 94.7% and 104.1% for all the impurities. The percentage relative standard deviation obtained for the repeatability was less than 4.0% at the specification level for all impurities. Forced degradation was performed to establish the stability‐indicating nature of the method and to know about the degradation products, the quality of a drug substance changes with time under the influence of stress conditions. Thus, the proposed method was validated and found to be specific, sensitive, linear, accurate, precise, reproducible, and beneficial for routine usage.


  • Stability indicating reversed‐phase‐high‐performance liquid chromatography method development and validation for pyridostigmine bromide and sodium benzoate in oral solution

    by Vaishnavi Chintala

    The present study focuses on the development of a simple, rapid, specific, and stability‐indicating HPLC method for the simultaneous analysis of pyridostigmine bromide (PGB) and sodium benzoate (SBN) in oral liquid dosage forms. Analytical techniques should enhance sensitivity and specificity for the estimation of pharmaceutical drug products. Stress studies were conducted under various International Conference on Harmonization (ICH) conditions for evaluation. The further optimized HPLC method was validated in accordance with the current ICH guidelines. Chromatographic separation was accomplished using a mobile phase consisting of a 950:50 v/v ratio of perchloric acid buffer and acetonitrile as mobile phase‐A, and 100% acetonitrile as mobile phase‐B. The flow rate is 1.0 mL/min, and the injection volume is 20 μL. Detection of components was carried out at 220 nm for PGB and 228 nm for SBN. The validated HPLC method demonstrated high specificity, with linearity ranging between 24 and 72 μg/mL for PGB and 5.2–15.6 μg/mL for SBN. The correlation coefficient for both drugs exceeded 0.999. The method demonstrated high accuracy, exceeding 97%. In stress studies, PGB was found to be sensitive to alkaline stress conditions. The results reveal the successful applicability of the current method for the estimation of PGB and SBN in its marketed formulation, which can be reasonably inferred to assess other formulation systems.


  • Quantification of Drospirenone- and Ethinyl Estradiol-Related Impurities in a Combined Pharmaceutical Dosage Form by a Chromatography Method With a QbD Robustness Study

    by Srinivasa Reddy Chinta, Vaishnavi Chintala, Vishnu Nandimalla, Rajyalakshmi Ch, Sasikiran Goud Ediga, Leela Prasad Kowtharapu, Naresh Kumar Katari

    Background: The estimation of drugs containing drospirenone (DRSP) and ethinyl estradiol (EE), and their related impurities, in low-dose oral contraceptive drug products is an extremely challenging target. The proposed research sought to develop and validate a stability-indicating method for quantifying drug substances and their related impurities in tablet formulation. Objective: To develop and validate a simple, specific, accurate, precise, and stability-indicating reverse-phase (RP)-HPLC method for quantification of DRSP, EE, and their impurities in accordance with International Conference on Harmonisation (ICH) guidelines. Method: The separation was achieved using an Agilent Zorbax SB C18 column (4.6 mm × 250 mm, 5 µm) with a detection wavelength of 215 nm and mobile phases A (100% acetonitrile) and B (acetonitrile–water, 1 + 3, v/v) at a flow rate of 1.3 mL/min and a column temperature of 40°C. Results: The recovery study of each impurity was conducted in the range of 24 to 72 µg/mL for DRSP-related impurities and 0.2 to 0.6 µg/mL for EE-related impurities with respect to the specification limit. A linearity study was conducted over a range of 1.5 to 90 µg/mL for DRSP and DRSP-related impurities, and 0.125 to 0.75 µg/mL for EE-related impurities. A Quality by Design (QbD) study demonstrated the method’s robustness. Conclusions: As per current guidelines, a stability-indicating method has been developed for the determination of impurities in DRSP/EE film-coated tablets. A QbD-based robustness test was performed and the method was found to be robust. Highlights: An accurate, precise, stability-indicating, gradient RP-HPLC method has been developed and validated to determine DRSP, EE, and nine related impurities in tablet formulation. A QbD technique was used to establish a robustness study.